Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen
Standard
Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen. / Lieb, V; Rink, M; Sikic, D; Keck, B.
in: UROLOGE, Jahrgang 55, Nr. 6, 06.2016, S. 805-12.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen
AU - Lieb, V
AU - Rink, M
AU - Sikic, D
AU - Keck, B
PY - 2016/6
Y1 - 2016/6
N2 - For approximately one decade, tyrosinkinase inhibitors (TKIs, smart drugs) have dramatically changed and improved the treatment of patients suffering from metastasized renal cell carcinoma. However, the different drugs have substantial side effects. Especially gastrointestinal symptoms may be problematic for patients. These side effects represent a challenge for the physician. On the one hand, dosage modifications and treatment interruption should be avoided to minimize the risk for progression. On the other hand, only mild side effects are tolerable for the patient. Based on a literature review, a clear overview of the incidence of possible side effects for the drugs axitinib, cabozantinib, pazopanib, sorafenib, and sunitinib is provided. Furthermore, we give a practical guide on how to prevent and treat the different gastrointestinal side effects. Finally, it is pointed out when dosage modifications or interruption of treatment are necessary and how to expeditiously re-escalate the treatment after mitigation of side effects.
AB - For approximately one decade, tyrosinkinase inhibitors (TKIs, smart drugs) have dramatically changed and improved the treatment of patients suffering from metastasized renal cell carcinoma. However, the different drugs have substantial side effects. Especially gastrointestinal symptoms may be problematic for patients. These side effects represent a challenge for the physician. On the one hand, dosage modifications and treatment interruption should be avoided to minimize the risk for progression. On the other hand, only mild side effects are tolerable for the patient. Based on a literature review, a clear overview of the incidence of possible side effects for the drugs axitinib, cabozantinib, pazopanib, sorafenib, and sunitinib is provided. Furthermore, we give a practical guide on how to prevent and treat the different gastrointestinal side effects. Finally, it is pointed out when dosage modifications or interruption of treatment are necessary and how to expeditiously re-escalate the treatment after mitigation of side effects.
KW - English Abstract
KW - Journal Article
U2 - 10.1007/s00120-016-0090-9
DO - 10.1007/s00120-016-0090-9
M3 - SCORING: Zeitschriftenaufsatz
C2 - 27146873
VL - 55
SP - 805
EP - 812
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 6
ER -